

Pfizer Company Survey – Jul 22

The Belgian Biobank Decree of 2018 requires “biobank notification” in Belgium for certain activities with biospecimens and also describes what is out of scope of the Decree. We are aware of differing interpretations of the Decree, and therefore are conducting this anonymous short survey to learn how the IPWG member companies are approaching it.

The Decree is only available in Dutch so if needed please consult your company’s local contact for input in order to provide accurate response to the survey questions.

Thank you for taking the time to complete this survey.

And here are the survey questions:

1. Does your company retain biospecimens from clinical trial sites in Belgium for use outside of (or after) the trial? Yes/No (If your response is No, the rest of the questions are not applicable.)
2. Are any of your biospecimen-related activities in scope of the Belgian Biobank Decree of 2018? Please describe. (If your response is No, the rest of the questions are not applicable.)
3. What approach or steps, if any, have you taken to comply with the Belgian Biobank Decree? Please describe your experience.
4. Has your company performed a biobank notification in Belgium? Please describe your experience.

Questions 2-4 are free text.